Dietary salt intake
Renal NO synthesis plays a role in acute and chronic regulation of sodium balance. In rats maintained on high salt diet, the expression of all NOS isoforms is increased in the inner medulla, while not significantly altered in the outer medulla and cortex. However, the most consistent finding in response to an altered dietary salt intake is a change of nNOS expression in the macula densa: a dietary salt restriction increases the expression of nNOS in the cortex and macula densa, whereas a high salt diet reduces macula densa nNOS expression. Blockade of nNOS with 8-nitroindazole prevents the effects of salt intake on nitrite excretion or the renal vascular responses to L-NAME. 
Interactions with sympathetic nerves
The sympathetic nervous system plays a role in the regulation of renal hemodynamics and sodium homeostasis. Basal NO synthesis may blunt the sympathetic vasoconstrictive effect in the isolated perfused rat kidney.
The relative insensitivity of the medullary circulation to the renal sympathetic activation is attributed to the medullary NO synthesis. NO also mediates the increased proximal tubular reabsorption of sodium that occurs with renal sympathetic nerve stimulation, which is in fact a rare example where NO is actually increasing the sodium reabsorption.
Interactions with O2 and angiotensin II The greater sensitivity of efferent arterioles to AII is related to a weaker influence of NO on these vessels.
Another important area of interaction between NO and AII is in the control of TGF sensitivity. AII is a powerful stimulus to sensitize TGF, whereas NO has an opposing effect on TGF sensitivity. An overweight of AII over NO will lead to vasoconstriction and body fluid volume reten-tion, resulting in an increase of arterial pressure. Conversely, a dominance of NO will strongly desensitize TGF, giving vasodilation, increased fluid volume excretion and reduction of blood pressure.
Pathophysiological implications of nitric oxide
Chronic kidney diseases
Chronic renal disease is characterized by a deficiency of NO bioactivity. The plasma from uremic patients has been shown to inhibit L-arginine transport in cultured endothelial cells 1) . In rats with 75% renal mass reduction and saline load for 4 weeks, NO excretion and NOS activity decreased along with the hypertension 2) . Moreover, eNOS mRNA, eNOS protein and eNOS activity are all decreased in human endothelial cell cultures exposed to erythrocytes from patients with end-stage renal disease 3) .
The plasma level of asymmetric dimethylarginine (ADMA, endogenous inhibitor of NOS) is positively correlated with systolic blood pressure in 5/6 nephrectomized rat model 4) , in which the increase of ADMA may be attributed to upregulation of protein methyltransferase, which catalyzes formation of ADMA, and downregulation of dimethylarginine dimethylaminohydrolase, which metabolizes ADMA.
Acute kidney injury
Benefits of providing NO donors before (but not following) the ischemic injury have been well documented.
A pretreatment with NO donor molsidomine or L-arginine ameliorated the renal injury in ischemic acute renal failure 5) . Provision of L-arginine at the time of ischemic injury also attenuated the reduction of glomerular filtration rate. Similarly, pretreatment with NO donor FK409 was shown to mitigate the ischemic renal injury, whereas treatment after ischemia worsened it 6) .
Hypertension

1) Spontaneous hypertension
In spontaneously hypertensive rats (SHR), the renal expression of NOS and the urinary excretion of NO are increased at 9-12 weeks of age 7) . The hypertension could be exaggerated by NOS inhibition. An enhanced O2 production and its interaction with NO play an important role in the pathogenesis of salt sensitivity in SHR. A two-fold increase of renal cortical nitrotyrosine deposition suggests an enhanced interaction of NO with ROS in SHR 8) , in which AII is implicated in increases of ROS and decreases of SOD. In SHR, the activity of antioxidant enzymes is diminished, and anti-oxidant treatment increases NO bioavailability to reduce the arterial pressure.
Nevertheless, the regulation of NO differs according to the age of the animal. With advanced age, SHR show reduced urinary NO excretion and depressed expression of NOS proteins in the kidney 9) . The decreased expression of NOS underscores the importance of these enzymes in the pathophysiology and maintenance of hypertension.
2) Dahl salt-sensitive hypertension
A reduced synthesis of NO in the renal medulla has been implicated in the pathogenesis of Dahl salt-sensitive (DS) hypertension. In response to salt loading, DS rats cannot but Dahl salt-resistant (DR) rats may markedly increase renal NOS activity 10) . In the kidney of DS rats, the activity of nNOS is decreased with its mRNA expression reduced 11) .
L-Arginine prevented the development of hypertension and normalized the pressure-natriuresis relationship in DS rats 12) . A selective iNOS inhibition with aminoguanidine augmented the increase of arterial pressure in DS rats on high salt intake 13) . Conversely, compensatory upregulation of iNOS expression and NOS activity may represent a novel mechanism regulating the increased volume load and blood pressure in DR rats. However, the activity eNOS in the kidney of DS rats seems to be unaltered.
Furthermore, DS rats on high-salt diet showed a significant correlation between the urinary excretion of ADMA and the degree of hypertension, suggesting that ADMA play a role in the pathogenesis of hypertension 14) . The hypertension in DS rats is also associated with renal artery hypertrophy, increased vascular and renal ET-1 protein contents, and glomerulosclerosis 10) .
The administration of tempol attenuates DS hypertension, indicating that the hypertension is also in part related to an increase in oxidative stress and a decrease in anti-oxidant capacity. It is indeed associated with marked decreases in medullary SOD activity and increases in oxidative tissue damage 15) .
3) Deoxycorticosterone acetate-salt hypertension
Deoxycorticosterone acetate (DOCA)-salt treatment increases the urinary excretion of nitrite and nitrate, along with the elevation of blood pressure 16) . NOS inhibition exaggerates the hypertensive response, whereas L-arginine markedly reduces the blood pressure and improves the cardiovascular dysfunction in DOCA-salt rats 17) . However, there may be uncoupling of NOS/NO and soluble guanylyl cyclase (sGC)/cGMP pathways in the inner medulla in this model of hypertension 18) . Although the urinary cGMP excretion increases after 1 week of DOCA-salt treatment, it gradually decreases to restore the normal values by the third week 16) . An attenuation of the hypertensive response by anti-oxidant treatment was also noted in DOCA-salt rats 19) . . The circulating plasma renin activity may bear no consistent relationship with the protective action of chronic AII blockade, because the plasma renin activity was increased, unchanged or decreased in this model of hypertension.
4)
In addition, NOS inhibition increases O2 activity and increases the urinary excretion of 8-isoprostane (a marker of enhanced O2 activity) 21) . The exaggerated hypertensive response during high-salt intake is abolished by concomitant administration of tempol 19) . It is suggested that O2 contributes to the development of salt sensitivity in L-NAME hypertension.
Liu et al. 22) observed no changes of plasma vasopressin levels in animals chronically treated with L-NAME. However, although administration of L-arginine and NO donors have variable effects on vasopressin secretion, the most common one is inhibition, and blockade of NO synthesis increases vasopressin secretion 23) . Furthermore, the hypertension is attenuated by inhibition of vasopressin 20) .
In this context, it is worth to note an upregulation of aquaporin-2 (AQP2) in the kidney in L-NAME hypertension 24) , which may in fact be related with altered vasopressin levels. On the contrary, a more recent study demonstrated a downregulation of AQP2, which may represent compensatory effects increasing the urinary excretion 25) .
An increased sympathetic drive may also be involved in the development of L-NAME hypertension. Acute ganglionic blockade produced a large fall of blood pressure, and chronic sympathectomy by daily injections of ganglionic blockers attenuated the hypertension. Furthermore, chronic bilateral renal denervation delayed and attenuated the hypertension 26) . In this context, water channels may also be affected in L-NAME-treated rats, since some water channels are under tonic excitatory influence of the sympathetic nerves 27) . On the contrary, it has been found that the hemodynamic actions of acute NOS inhibition in the unstressed rat are independent of the sympathetic nervous system. A more recent study also failed to demonstrate changes in renal sympathetic nerve activity in L-NAME hypertension in conscious rabbits, indicating that the renal nerves do not mediate the increase of blood pressure 28) .
Prostacyclin (PGI2) inhibits NO release from cultured endothelial cells 29) . In the dog kidney, the full renal .
5) Two-kidney, one-clip hypertension
Chronic two-kidney, one-clip (2K1C) hypertension has been associated with an impaired endothelium-dependent vasorelaxation 31) . Both early and chronic phases of 2K1C hypertension are augmented by NO synthesis inhibitors.
Furthermore, 2K1C hypertension is associated with reduced levels of eNOS proteins in the medulla of both clipped and contralateral kidneys, being causally related with reduction of medullary blood flow 32) . In the early reversal of hypertension and changes of renal function following unclipping of the clipped artery, an upregulation of eNOS and enhanced release of NO is an important component 33) . It is likely that NO contributes a significant vasodilator tone to buffer the hypertension and maintains perfusion of kidneys in this model.
6) Angiotensin II-induced hypertension
NO has been shown to provide renoprotection in AIIinduced hypertension. Salt-sensitive hypertension develops after short-term exposure to AII, in association with a loss of intrarenal NO formation that could alter the ability of the kidney to excrete a salt load 34) . The sodium-retaining effect of AII in the absence of NO is mediated mainly by enhanced O2 activity 35) , suggesting that an interaction between NO and O2 in the kidney plays an important role in the development of salt sensitivity and hypertension. In fact, nicotinamide adenine dinucleotide phosphate (NADPH) oxidase -one important source for free superoxide -was activated and the superoxide production was enhanced due to AII 10) . AII can also reduce ecSOD expression 36) .
In rats with 2-kidney, 1 figure-8 wrap (Grollman) hypertension, AII mediates renal production of bradykinin, which, in turn, releases NO and cGMP via stimulation of AT2R 37) . Aortic banding resulted in significant upregulation of eNOS, iNOS and nNOS in the renal cortex and medulla 38) . The aortic coarctation-induced hypertension is associated with increased nitrotyrosine abundance in all tissues exposed to high arterial pressure, denoting enhanced ROS-mediated inactivation and sequestration of NO 39) .
7) Other models of hypertension 40) . In fructose-fed rats, while the vascular expression of NOS proteins is not altered 41) , the medullary NO production is reduced during high sodium load, resulting in salt-sensitive hypertension 42) . The renal expression of iNOS and eNOS mRNA is reduced in hypertension induced by adrenocorticotropic hormone (ACTH) or corticosterone 43) . 
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A chronic exposure to low levels of lead results in a marked elevation of blood pressure, in association with significant reduction in urinary NO excretion and upregulation of eNOS and iNOS abundance in the kidney 44) .
Chronic elevation of plasma vasopressin levels enhances the medullary eNOS protein expression, which enables sustained elevations of NO concentrations to buffer the hypertensive effects of vasopressin 45) . It has been also found that the hypertensive effect of intravenous infusion of norepinephrine was chronically buffered by the 2 α receptor-mediated increase of NOS activity within the renal medulla 46) . In hydronephrotic rats, a reduced NO availability through reduced expression of nNOS and eNOS proteins in the diseased kidney and subsequent resetting of TGF mechanism plays an important role in the development of hypertension 47) . Although eNOS protein and tissue nitrate contents are decreased along with enhanced ET-1 proteins in the aorta of type II 11 -hydroxysteroid β dehydrogenase-deficient rats 48) , their changes in the kidney have not been documented. Oral contraceptive users exhibit elevated AII levels and AT1R expression, of which hemodynamic effects may be modulated by an increased activity of NO pathway 49) .
